Next-Generation Nanobody Immunotherapy Targeting MAC-1/ITGAM for HPV Infection

VHH-P846 is an innovative humanized nanobody immunoconjugate engineered to specifically target the Integrin alphaMbeta2 (MAC-1) Receptor, also known as integrin subunit alpha M (ITGAM). Currently in the biological testing phase, this novel construct is designed for the treatment of Papilloma Virus (HPV) Infection. By leveraging advanced single-domain antibody technology, VHH-P846 aims to enhance immune recognition and facilitate precise antigen delivery. Its unique mechanism and targeted activity underline its potential as a breakthrough immunotherapeutic for addressing HPV-associated pathologies.

Licensing Opportunity

VHH-P846 is available for partnering and out-licensing opportunities. We actively welcome inquiries from biopharmaceutical companies and research institutions interested in collaborative development or commercialization of this promising nanobody-based immunotherapy.

Development Phase

Modality

VHH-P846 employs a camelid-derived single heavy chain variable domain antibody as its foundation, representing a next-generation nanobody platform. The construct is engineered as an immunoconjugate, combining a nanobody against CD11b on dendritic cells with the HPV16 E7 antigen. This modular, single-domain design imparts exceptional molecular stability, deep tissue penetration, and reduced immunogenicity due to its small molecular size. These features are particularly advantageous for delivering antigens and modulating immune responses in the context of HPV infection, supporting enhanced therapeutic efficacy and flexibility for vaccine strategies.

Target

MAC-1/ITGAM is an integrin primarily expressed on myeloid lineage immune cells, including dendritic cells, monocytes, and macrophages. This molecule plays a critical role in immune cell adhesion, migration, and signal transduction, which are essential for effective immune surveillance and response. Targeting MAC-1/ITGAM enables the strategic delivery of immunomodulatory agents to antigen-presenting cells, facilitating robust antitumor and antiviral immunity. In HPV infection, redirecting vaccine antigens to immune subsets expressing MAC-1/ITGAM can improve antigen presentation and T-cell priming, addressing a key challenge in therapeutic vaccination. The strategic focus on MAC-1/ITGAM in VHH-P846 underscores its potential to advance the field of immunotherapy for HPV-related diseases by leveraging the pivotal role of this target in immune functionality.

Mechanism of Action

VHH-P846 is designed to engage MAC-1/ITGAM on dendritic cells, acting as both a signal transduction modulator and a targeted antigen delivery platform. By binding to MAC-1/ITGAM, the nanobody-based immunoconjugate directs the HPV16 E7 antigen to critical immune cells, augmenting antigen uptake, processing, and presentation. This targeted interaction is expected to intensify adaptive immune responses against HPV-infected or transformed cells. Beyond its initial configuration, the nanobody format of VHH-P846 offers considerable flexibility for further development—such as antibody-drug conjugates or bispecific constructs—broadening potential therapeutic applications rooted in precise immunomodulation.

Papilloma Virus (HPV) Infection

Human papillomavirus (HPV) infection is a pervasive global health concern, implicated in a wide spectrum of diseases, from benign warts to multiple anogenital and oropharyngeal cancers. The majority of sexually active individuals are exposed to HPV, and persistent infections, particularly with oncogenic subtypes like HPV16, are the primary cause of cervical and other HPV-driven cancers. Existing interventions include prophylactic vaccines and ablative or cytotoxic therapies for established lesions and malignancies. However, therapeutic gaps remain for clearing persistent infections and treating HPV-driven cancers, especially in resource-limited settings or advanced disease stages. Current therapeutic strategies often face challenges related to immune evasion, limited efficacy in established disease, and substantial unmet needs in immunocompromised populations. VHH-P846, by targeting antigen delivery to dendritic cells through MAC-1/ITGAM and incorporating tumor-associated antigens, holds promise to address these critical limitations by promoting strong cellular immunity and overcoming conventional barriers in HPV immunotherapy.